PTC Therapeutics, Inc. (PTCT) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
PTCT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, PTC Therapeutics, Inc. (PTCT) trades at a price-to-earnings ratio of 8.3x, with a stock price of $64.49 and trailing twelve-month earnings per share of $-2.26.
The current P/E is roughly in line with its 5-year average of 8.0x. Over the past five years, PTCT's P/E has ranged from a low of 7.0x to a high of 9.8x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, PTCT trades at a 63% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, PTCT trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PTCT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PTCT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $10B | 30.1 | -Best | -19% | |
| $39B | 127.0 | -Best | +207%Best | |
| $4B | 9.9Lowest | -Best | +68% | |
| $9B | 43.4 | -Best | +128% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
PTCT Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $75.96 | $7.74 | 9.8x | +23% |
| FY2025 Q3 | $61.37 | $8.56 | 7.2x | -10% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $48.84 | $6.97 | 7.0x | -12% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $50.96 | $6.51 | 7.8x | -2% |
Average P/E for displayed period: 8.0x
See PTCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTCT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTCT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPTCT — Frequently Asked Questions
Quick answers to the most common questions about buying PTCT stock.
Is PTCT stock overvalued or undervalued?
PTCT trades at 8.3x P/E, near its 5-year average of 8.0x. The 75th percentile ranking places valuation within normal historical bounds.
How does PTCT's valuation compare to peers?
PTC Therapeutics, Inc. P/E of 8.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is PTCT's PEG ratio?
PTCT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.